eGFR evolution (MDRD, mL/min/1.73 m2): evaluation 12 months after inclusion
Study population . | MDRD M0 . | MDRD M12 . | P-value . | Change in M0–M12 . |
---|---|---|---|---|
Entire study population | ||||
CNI group (n = 68) | 27.7 ± 8.1 | 25.5 ± 12.5 | P = .01 | –2.2 ± 7.2 |
CNI to belatacept group (n = 64) | 25.5 ± 6.1 | 28.6 ± 9.6 | P = .0003 | +3.2 ± 8.4 |
P = .05 | P = .15 | P < .0001 | ||
Study population after exclusion of patients with graft loss between M0 and M12 | ||||
CNI group (n = 60) | 29.2 ± 7.3 | 28.2 ± 10.7 | P = .0281 | 0.9 ± 6.6 |
CNI to belatacept group (n = 60) | 25.7 ± 6.1 | 30.2 ± 79.6 | P < .0001 | +4.6 ± 6.3 |
P = .0004 | P = .31 | P < .0001 |
Study population . | MDRD M0 . | MDRD M12 . | P-value . | Change in M0–M12 . |
---|---|---|---|---|
Entire study population | ||||
CNI group (n = 68) | 27.7 ± 8.1 | 25.5 ± 12.5 | P = .01 | –2.2 ± 7.2 |
CNI to belatacept group (n = 64) | 25.5 ± 6.1 | 28.6 ± 9.6 | P = .0003 | +3.2 ± 8.4 |
P = .05 | P = .15 | P < .0001 | ||
Study population after exclusion of patients with graft loss between M0 and M12 | ||||
CNI group (n = 60) | 29.2 ± 7.3 | 28.2 ± 10.7 | P = .0281 | 0.9 ± 6.6 |
CNI to belatacept group (n = 60) | 25.7 ± 6.1 | 30.2 ± 79.6 | P < .0001 | +4.6 ± 6.3 |
P = .0004 | P = .31 | P < .0001 |
eGFR evolution (MDRD, mL/min/1.73 m2): evaluation 12 months after inclusion
Study population . | MDRD M0 . | MDRD M12 . | P-value . | Change in M0–M12 . |
---|---|---|---|---|
Entire study population | ||||
CNI group (n = 68) | 27.7 ± 8.1 | 25.5 ± 12.5 | P = .01 | –2.2 ± 7.2 |
CNI to belatacept group (n = 64) | 25.5 ± 6.1 | 28.6 ± 9.6 | P = .0003 | +3.2 ± 8.4 |
P = .05 | P = .15 | P < .0001 | ||
Study population after exclusion of patients with graft loss between M0 and M12 | ||||
CNI group (n = 60) | 29.2 ± 7.3 | 28.2 ± 10.7 | P = .0281 | 0.9 ± 6.6 |
CNI to belatacept group (n = 60) | 25.7 ± 6.1 | 30.2 ± 79.6 | P < .0001 | +4.6 ± 6.3 |
P = .0004 | P = .31 | P < .0001 |
Study population . | MDRD M0 . | MDRD M12 . | P-value . | Change in M0–M12 . |
---|---|---|---|---|
Entire study population | ||||
CNI group (n = 68) | 27.7 ± 8.1 | 25.5 ± 12.5 | P = .01 | –2.2 ± 7.2 |
CNI to belatacept group (n = 64) | 25.5 ± 6.1 | 28.6 ± 9.6 | P = .0003 | +3.2 ± 8.4 |
P = .05 | P = .15 | P < .0001 | ||
Study population after exclusion of patients with graft loss between M0 and M12 | ||||
CNI group (n = 60) | 29.2 ± 7.3 | 28.2 ± 10.7 | P = .0281 | 0.9 ± 6.6 |
CNI to belatacept group (n = 60) | 25.7 ± 6.1 | 30.2 ± 79.6 | P < .0001 | +4.6 ± 6.3 |
P = .0004 | P = .31 | P < .0001 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.